Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IoM AIDS Report Urges International Treatment Quality Assurance Standard

Executive Summary

The Institute of Medicine recommends the creation of international quality assurance systems to ensure the quality of AIDS treatments for the developing world

You may also be interested in...



GSK To Supply Combivir For NIH Trial Following Letter From Rep. Waxman

GlaxoSmithKline will provide Combivir at a discounted rate for a clinical trial on HIV treatment in developing countries following a letter from Rep. Henry Waxman (D-Calif.) admonishing the company for withdrawing from the study

FDA Guidance On Combo HIV Products Will Allow Reviews In Six Weeks

FDA is setting a goal of reviewing fixed-dose combinations of HIV drugs in six weeks as part of the Bush Administration's $15 bil. Emergency Plan for AIDS Relief

Global HIV/AIDS Bill Clears Senate; Kennedy Pricing Amendment Fails

The Bush Administration's global HIV/AIDS initiative is on a fast track to becoming law following Senate passage of HR 1298

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel